Ultragenyx Pharmaceutical Inc.
Moat Score — Ultragenyx Pharmaceutical Inc.
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Ultragenyx holds a deep patent estate of over 300 issued patents plus orphan-drug regulatory exclusivities across Crysvita, Dojolvi, Evkeeza, and Mepsevii. Its in-house AAV gene-therapy manufacturing capability is itself a hard-to-replicate asset, since gene-therapy manufacturing capacity is scarce industry-wide. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Ultragenyx is not a low-cost operator in any sense: R&D expense of $750 million exceeded total revenue of $673 million in FY2025, reflecting the inherent expense of running enzyme-replacement, gene-therapy, and antisense programs in parallel for diseases with tiny patient populations. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | Ultra-rare diseases like MPS VII (Mepsevii) or LC-FAOD (Dojolvi) frequently have no approved pharmacologic alternative at all, giving Ultragenyx substantial pricing power once a product like Crysvita is approved and reimbursed, evidenced by Crysvita alone generating $481 million in FY2025 from a genetically narrow patient population. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in rare-disease biopharmaceuticals; a patient's benefit from Crysvita or Dojolvi does not increase with the number of other patients or physicians using the drug. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Patients stabilized on a chronic enzyme-replacement therapy like Crysvita or Mepsevii, and the specialist physicians managing them, have real inertia against switching given the risk of destabilizing a rare, serious condition, but this is a moderate rather than extreme switching cost since there is often no alternative therapy to switch to in the first place. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 4 / 5 | Diseases like MPS VII or Sanfilippo syndrome (UX111) affect only a few hundred to a few thousand patients globally, a market simply too small to profitably support two competing branded therapies, which is why most Ultragenyx programs described in its 10-K face no clinical-stage competitor at all. |